- Tazarotenic acid
-
- $53.00
-
2026-05-11
- CAS:118292-41-4
- Purity: 98.64%
- Supply Ability: 10g
|
| | AGN 190299 Basic information |
| Product Name: | AGN 190299 | | Synonyms: | 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-;6-((3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-3-pyridinecarboxylic acid;6-(2-(4,4-Dimethylthiochroman-6-yl)ethynyl)nicotinic acid;AGN 190299;6-[[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran)-6-yl]ethynyl]nicotinic acid;6-[2-(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridine carboxylic acid;Tazarotene Impurity 1（Tazarotenic Acid）;Tazarotenic acid (AGN 190299) | | CAS: | 118292-41-4 | | MF: | C19H17NO2S | | MW: | 323.41 | | EINECS: | 604-604-1 | | Product Categories: | Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Retinoids;Sulfur & Selenium Compounds | | Mol File: | 118292-41-4.mol |  |
| | AGN 190299 Chemical Properties |
| Melting point | >190°C (dec.) | | Boiling point | 527.5±50.0 °C(Predicted) | | density | 1.31 | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly, Sonicated), Methanol (Slightly, Sonicated) | | pka | 3.30±0.10(Predicted) | | form | Solid | | color | Pale Yellow to Brown | | InChI | 1S/C19H17NO2S/c1-19(2)9-10-23-17-8-4-13(11-16(17)19)3-6-15-7-5-14(12-20-15)18(21)22/h4-5,7-8,11-12H,9-10H2,1-2H3,(H,21,22) | | InChIKey | IQIBKLWBVJPOQO-UHFFFAOYSA-N | | SMILES | CC1(C)CCSC2=C1C=C(C#CC3=CC=C(C(O)=O)C=N3)C=C2 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | AGN 190299 Usage And Synthesis |
| Chemical Properties | Pale Yellow Solid | | Uses | Tazarotenic acid is the major active metabolite of Tazarotene (T010050). | | Uses | The principle active metabolite | | Definition | ChEBI: A thiochromane that is acetylene in which the hydrogens are replaced by 5-carboxypyridin-2-yl and 4,4-dimethylthiochroman-6-yl groups. It is the active form of the prodrug tazarotene. | | Biological Activity | Tazarotene is transformed to tazarotenic acid with the help of esterases. Tazarotenic acid regulates the pathogenic aspects of psoriasis through normalizing abnormal keratinocyte differentiation. It possesses strong anti-hyperproliferative effects in skin and reduces inflammation.', 'Tazarotenic acid, an active metabolite of tazarotene, is a potent and selective agonist of the retinoid receptor (RAR) th at binds to RARα, RARβ, and RARγ. Tazarotenic acid relatively selective activates RARβ and RARγ. Tazarotenic acid is a first xenobiotic substrate of human retinoic acid hydroxylase CYP26A1 and CYP26B1. | | in vivo | Assessment of Pharmacokinetics (PK) profile of Tazarotenic acid (Compound AGN 190299) after an intravenous of AGN 190168 in rats[1]
.
| Male | Female | Male | | Dose (mg kg-1) | 4.4 | 4.4 | 0.49 | | AUC (μg h mL-1) | 9.31 (2.14) | 9.78 (1.36) | 0.594 (0.95) | | CL (mL min-1 kg-1) | 7.96 (1.59) | 7.62 (0.85) | 14.0 (2.2) | | k (h-1) | 0.562 (0.339) | 0.820 (0.146) | 0.741 (0.115) | | T1/2 (h) | 1.64 (0.92) | 0.86 (0.14) | 0.95 (0.16) | | V0 (L kg-1)
| 0.43 (0.05) | 0.49 (0.06) | 1.31 (1.15) | | Vβ (L kg-1)
| - | - | 1.14 (0.09) | | Vmax (μg min-1)
| 9.08 (2.89) | 6.09 (1.22) | - | | Km (μg mL-1) | 7.09 (1.35) | 5.12 (1.19) | - |
|
| | AGN 190299 Preparation Products And Raw materials |
|